Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter Joint Phase II Clinical Study to Evaluate the Efficacy and Safety of Dasatinib Very Low Dose Therapy in Elderly Patients with Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

Trial Profile

A Multicenter Joint Phase II Clinical Study to Evaluate the Efficacy and Safety of Dasatinib Very Low Dose Therapy in Elderly Patients with Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 29 Jan 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dasatinib (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Therapeutic Use
  • Acronyms DAVLEC
  • Most Recent Events

    • 14 Dec 2021 Primary endpoint (Major molecular response (MMR) achievement rate at 12 months after initiation of treatment) has been met, as per results presented at the 63rd American Society of Hematology Annual Meeting and Exposition.
    • 14 Dec 2021 Results assessing the efficacy and safety of a reduced initial dose of DAS (20 mg/day) in the elderly with chronic phase chronic myeloid leukemia , presented at the 63rd American Society of Hematology Annual Meeting and Exposition.
    • 07 Nov 2021 Planned number of patients changed from 100 to 50.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top